Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 2

Status

Terminated 3Completed 2Unknown 1

Sponsor Class

OTHER 3NIH 3

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Carcinoma, Hepatocellular 66Carcinoma, Renal Cell 38Liver Neoplasms 20Neoplasm Metastasis 17Carcinoma, Non-Small-Cell Lung 16Neoplasms 15Breast Neoplasms 15Melanoma 13Thyroid Neoplasms 10Leukemia, Myeloid, Acute 10Sarcoma 9Lung Neoplasms 8Kidney Neoplasms 8Prostatic Neoplasms 7Ovarian Neoplasms 7Urinary Bladder Neoplasms 6Pancreatic Neoplasms 6Glioblastoma 6Brain Neoplasms 6Colorectal Neoplasms 5Carcinoma, Medullary 5Thyroid Carcinoma, Anaplastic 4Stomach Neoplasms 4Rectal Neoplasms 4Gliosarcoma 4Gallbladder Neoplasms 4Colonic Neoplasms 4Breast Neoplasms, Male 4Thyroid Diseases 3Thyroid Cancer, Papillary 3

Interventions

Gemcitabine 83Cisplatin 59pembrolizumab 28Paclitaxel 21Nivolumab 21Carboplatin 21Cystectomy 20Docetaxel 18durvalumab 17atezolizumab 17Magnetic Resonance Spectroscopy 16Specimen Handling 15Radiotherapy 14avelumab 13Mitomycin 13Sunitinib 12Doxorubicin 12Methotrexate 11Fluorouracil 11Vinblastine 10Filgrastim 7BCG Vaccine 7Sorafenib 6Ipilimumab 6Immunoglobulin G 6Disulfides 6Biopsy 6enfortumab vedotin 5cabozantinib 5Trastuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Urinary Bladder Neoplasms × Sorafenib × Clear all
NCT00112671 2018-07-27

Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract

National Cancer Institute (NCI)

Phase 2 Completed
17 enrolled 9 charts
Genitourinary

Urinary Bladder Neoplasms

NCT00461851 2017-12-14

Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma

Yale University

Phase 2 Completed
17 enrolled 10 charts
Genitourinary

Urinary Bladder Neoplasms

NCT00714948 2015-11-16

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
2 enrolled 5 charts
Genitourinary

Urinary Bladder Neoplasms

NCT00112905 2014-05-30

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

National Cancer Institute (NCI)

Phase 2 Terminated
27 enrolled 8 charts
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT01222676 2013-08-12

Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder

National Cancer Institute (NCI)

Phase 2 Unknown
45 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT01215266 2011-09-08

Sorafenib in Urothelium Cancer of Bladder

Association of Urologic Oncology (AUO)

Phase 2 Terminated
98 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡